Smoking reduces breast tenderness during oral estrogen-progestogen therapy.
We wished to study the influence of smoking upon the occurrence of breast tenderness during oral estrogen-progestogen therapy (EPT). Data from 626 healthy postmenopausal women participating in three double-blind, randomized, controlled long-term trials of EPT versus placebo were included. The studies covered sequential, continuous and interrupted regimens of estradiol opposed by a selection of progestins. All studies were mono-center studies and performed in the period 1988-1997. Data on breast tenderness were collected from adverse event reporting and information on smoking status was obtained by interview. Smoking was associated with an earlier age at menopause (difference: 1.3 years, p < 0.001) and a slightly lower body mass index (difference: 0.8 kg/m2, p < 0.01). Smoking women in the EPT groups had significantly lower on-treatment estradiol levels compared to non-smoking women (p < 0.001), whereas no differences were observed in the placebo group. In parallel, the incidence of breast tenderness during EPT was reduced by about one-half (p < 0.001) in smokers compared to non-smokers, whereas no differences were seen on placebo. Current smoking reduces the incidence of breast tenderness in women receiving oral EPT. This may be caused by the increased degradation of estradiol during smoking.